within Pharmacolibrary.Drugs.ATC.N;

model N02AX51
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.09,
    Cl             = 0.02,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 600,            
    Vdp             = 0.005,
    k12             = 120,
    k21             = 120
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02AX51</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tilidine is a synthetic opioid analgesic used for the treatment of moderate to severe pain. It is often administered in combination with naloxone, an opioid antagonist, to prevent misuse and reduce the risk of abuse. This combination is commonly prescribed in some European countries but is not approved in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are estimated for healthy adult individuals based on available literature for tilidine and naloxone combination, as direct pharmacokinetic models for the fixed-dose combination under ATC code N02AX51 are not explicitly published.</p><h4>References</h4><ol><li><p>Brennscheidt, U, et al., &amp; Seiler, KU (2007). Pharmacokinetics of tilidine and naloxone in patients with severe hepatic impairment. <i>Arzneimittel-Forschung</i> 57(2) 106–111. DOI:<a href=\"https://doi.org/10.1055/s-0031-1296591\">10.1055/s-0031-1296591</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17396621/\">https://pubmed.ncbi.nlm.nih.gov/17396621</a></p></li><li><p>Brennscheidt, U, et al., &amp; Thomann, P (2000). Pharmacokinetics of nortilidine and naloxone after administration of tilidine/naloxone solution or tilidine/naloxone sustained release tablets. <i>Arzneimittel-Forschung</i> 50(11) 1015–1022. DOI:<a href=\"https://doi.org/10.1055/s-0031-1300326\">10.1055/s-0031-1300326</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11148857/\">https://pubmed.ncbi.nlm.nih.gov/11148857</a></p></li><li><p>Högger, P, &amp; Rohdewald, P (1999). Comparison of tilidine/naloxone, tramadol and bromfenac in experimental pain: a double-blind randomized crossover study in healthy human volunteers. <i>International journal of clinical pharmacology and therapeutics</i> 37(8) 377–385. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10475140/\">https://pubmed.ncbi.nlm.nih.gov/10475140</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02AX51;
